Safety study of a diagnostic injection in healthy Chinese adults
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new imaging agent called flotufolastat F-18 in healthy volunteers to see how it travels through the body and how safe it is. The results will help doctors use this agent for imaging in future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- Your body mass index (BMI) is between 19 and 26.
- You are generally healthy, with no major medical conditions like heart disease, diabetes, or cancer.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after.
- You have not taken any medications, including over-the-counter drugs or herbal remedies, in the past 14 days.
- You can lie still inside an imaging scanner (like an MRI) and are not claustrophobic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
This trial tests a new radioactive tracer called ⁶⁸Ga-FC516 to see how well it works for imaging prostate cancer. It may help doctors find and monitor prostate cancer more accurately.
This trial tests a new PET scan (a type of imaging that uses a radioactive tracer) to see how well it can find prostate cancer after focal therapy. If you join, you'll get the scan before and after your treatment to help doctors see if any cancer is left.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This study tests a new imaging method (PET scan) that uses a special tracer to find prostate cancer cells, whether it's the first diagnosis or a recurrence after treatment. The goal is to see how well this imaging works for locating cancer in the body.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.